Prospective study comparing Xalatan ® eye drops and two similar generics as to the efficacy and safety profile

Abstract

Purpose:

To evaluate the efficacy and safety between two generic prostaglandins Lataz–Xalaprost (Greece) and the corresponding original drops (Xalatan^®).

Material and methods:

In this prospective randomized study, 60 patients diagnosed with open-angle glaucoma or ocular hypertension were enrolled, who had never received antiglaucoma treatment. Subjects were divided randomly into three groups (Xalatan, Lataz, and Xalaprost groups) and they were studied over 16 weeks. At each visit, the mean applanation tonometry values and tear break-up time were measured. The Ocular Surface Disease Index questionnaire was used to evaluate patient’s symptoms.

Results:

There was a statistically significant difference (p < 0.001) in the mean values of the intraocular pressure between the baseline and the last visit (Xalatan group: from 23.11 ± 1.61 mmHg to 15.81 ± 1.22 mmHg, Lataz group: from 23.26 ± 1.33 mmHg to 15.80 ± 1.47 mmHg, and Xalaprost group: from 23.08 ± 1.45 mmHg to 16.08 ± 1.38 mmHg). Both generic eye drops showed mean percentage intraocular pressure reduction comparable to the standards of prostaglandin analogues (Xalatan: 31.57%, Lataz: 32.06%, and Xalaprost: 30.34%). Xalatan reduced the tear break-up time less, followed by Lataz and then by Xalaprost (Xalatan: from 8.5 to 8 s, Lataz: from 8.2 to 7.4 s, and Xalaprost: from 8.7 to 7.7 s). Xalatan presented the best safety profile, followed by Lataz and least was Xalaprost, according to Ocular Surface Disease Index questionnaire’s results.

Conclusion:

No significant difference was recorded in the effectiveness of each generic prostaglandin compared to the original. Furthermore, no patient had to change medication. The differences that arose in the safety profile of the three eye drops suggest a prompt closer initial monitoring of patients who are administered generic eye drops.

Keywords

Efficacy generics glaucoma Latanoprost safety profile

Get full access to this article

View all access options for this article.

References

Alm

. Latanoprost in the treatment of glaucoma. Clin Ophthalmol 2014; 8: 1967–1985.

Stein

Ayyagari

Sloan

et al . Rates of glaucoma medication utilization among persons with primary open-angle glaucoma, 1992 to 2002. Ophthalmology 2008; 115: 1315–1319.

Diestelhorst

Nordmann

Toris

. Combined therapy of pilocarpine or latanoprost with timolol versus latanoprost monotherapy. Surv Ophthalmol 2002; 47: S155–S161.

Nordstrom

Friedman

Mozaffari

et al . Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol 2005; 140(4): 598–606.

Russo

Riva

Pizzolante

et al . Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review. Clin Ophthalmol 2008; 2(4): 897–905.

Van der Valk

Webers

Schouten

et al . Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 2005; 112(7): 1177–1185.

Parrish

Palmberg

Sheu

. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003; 135(5): 688–703.

Lin

Zhao

Chew

et al . Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension. Ann Pharmacother 2014; 48(12): 1585–1593.

Zore

Harris

Tobe

et al . Generic medications in ophthalmology. Br J Ophthalmol 2013; 97(3): 253–257.

10.

Digiuni

Manni

Vetrugno

et al . An evaluation of therapeutic noninferiority of 0.005% latanoprost ophthalmic solution and xalatan in patients with glaucoma or ocular hypertension. J Glaucoma 2013; 22(9): 707–712.

11.

Borgheini

. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther 2003; 25(6): 1578–1592.

12.

Chambers

. Ophthalmic generics—are they really the same? Ophthalmology 2012; 119(6): 1095–1096.

13.

Aref

. Generic drugs for the treatment of ocular conditions: changing the treatment landscape. Expert Rev Clin Pharmacol 2014; 7(5): 551–553.

14.

Kahook

Fechtner

Katz

et al . A comparison of active ingredients and preservatives between brand name and generic topical glaucoma medications using liquid chromatography-tandem mass spectrometry. Curr Eye Res 2012; 37(2): 101–108.

15.

Angmo

Wadhwani

Velpandian

et al . Evaluation of physical properties and dose equivalency of generic versus branded latanoprost formulations. Int Ophthalmol 2017; 37(2): 423–428.

16.

Cantor

. Ophthalmic generic drug approval process: implications for efficacy and safety. J Glaucoma 1997; 6: 344–349.

17.

Mammo

Flanagan

James

et al . Generic versus brand-name North American topical glaucoma drops. Can J Ophthalmol 2012; 47(1): 55–61.

18.

Patel

Spaeth

. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg 1995; 26(3): 233–236.

19.

Ravinet

Mermoud

Brignoli

. Four years later: a clinical update on latanoprost. Eur J Ophthalmol 2003; 13(2): 162–175.

20.

Martin

. Clinical experience with latanoprost: a retrospective study of 153 patients. Acta Ophthalmol Scand 1999; 77(3): 336–339.

21.

Alm

Widengård

. Latanoprost: experience of 2-year treatment in Scandinavia. Acta Ophthalmol Scand 2000; 78(1): 71–76.

22.

Kingman

. Glaucoma is second leading cause of blindness globally. Bull World Health Organ 2004; 82: 887–888.

23.

Quigley

Broman

. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90: 262–267.

24.

Tham

Wong

et al . Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 2014; 121(11): 2081–2090.

25.

Strmen

Jancus

Okkelova

. Clinical trial of the generic product UNILAT following its efficiency and safety in glaucoma and intraocular hypertension. Cesk Slov Oftalmol 2010; 66: 258–261.

26.

Golan

Rosenfeld

Shemesh

et al . Original and generic latanoprost for the treatment of glaucoma and ocular hypertension: are they really the same? Clin Exp Pharmacol Physiol 2015; 42(2): 220–224.

27.

Allaire

Dietrich

Allmeier

et al . Latanoprost 0.005% test formulation is as effective as Xalatan® in patients with ocular hypertension and primary open-angle glaucoma. Eur J Ophthalmol 2012; 22(1): 19–27.

28.

Narayanaswamy

Neog

Baskaram

et al . A randomized, crossover, open label pilot study to evaluate the efficacy and safety of Xalatan in comparison with generic latanoprost (latoprost) in subjects with primary open angle glaucoma or ocular hypertension. Indian J Ophthalmol 2007; 55: 127–131.

29.

Takada

Okada

Fujita

et al . A patient with corneal epithelial disorder that developed after administration of a latanoprost generic, but not a brand-name drug, eye drop. Case Rep Ophthalmol 2012; 2012: 536746.

30.

Leitritz

Lipp

Voykov

et al . Original preparations versus generics—latanoprost: how similar is different? Ophthalmologe 2015; 112(2): 127–139.

31.

Velpandian

Kotnala

Halder

et al . Stability of latanoprost in generic formulations using controlled degradation and patient usage simulation studies. Curr Eye Res 2015; 40(6): 561–571.

32.

Morgan

Proniuk

Blanchard

et al . Effect of temperature and light on the stability of latanoprost and its clinical relevance. J Glaucoma 2001; 10(5): 401–405.

33.

Van Santvliet

Ludwig

. Determinants of eye drop size. Surv Ophthalmol 2004; 49(2): 197–213.

34.

Connor

Severn

. Force requirements in topical medicine use: the squeezability factor. Eye 2011; 25(4): 466–469.